Navigation Links
IBT Laboratories Expands its Menu of Tests for Immune Deficiency
Date:12/2/2008

LENEXA, Kan., Dec. 2 /PRNewswire/ -- IBT Laboratories, a leading clinical-diagnostics and biomedical-research laboratory specializing in immunology and allergy assays, announced that it has launched two tests to evaluate the response of patients whose immune systems may be compromised due to a primary immunodeficiency disorder, chemotherapy drugs, or because they are taking immuno-suppressing drugs to prevent rejection of a transplant. The company launched the two new assays, the T Cell FxTM test and the Mannan Binding Lectin (MBL) Pathway Function Test, at the November 2008 meeting of the American College of Allergy Asthma and Immunology in Seattle.

According to IBT Founder and Chief Executive Officer, John F. Halsey, Ph.D., these two tests provide physicians with much greater insight into a patient's immunology profile than was possible before. "We rely on our body's immune system to defend us from infectious disease. When a patient has an unusual number of infections, physicians need a complete assessment of the capabilities of the patient's immune system to respond to challenge by microorganisms. Both innate and adaptive immunity need to be evaluated. Previously, these kinds of tests were only used by the research community, and were not available in the clinical-diagnostics laboratory."

Regarding company strategy, Dr. Halsey commented, "Our assay-development strategy at IBT is to work closely with leading allergists and immunologists to translate the latest research findings into new diagnostic tests that will help them better understand and manage their patients' health status, and ultimately improve health outcomes."

The MBL pathway is one of the most important components of the innate immune system. IBT has developed a unique and quantitative serum test (MBL Pathway Function Test) to evaluate the effectiveness of this pathway. This test will be particularly useful to
'/>"/>

SOURCE IBT Laboratories
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Romark Laboratories Raises $18 Million in Institutional Financing
5. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
6. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
7. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
8. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
9. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
10. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
11. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... (OFT) approval condition to the announced tender offer for all of ... As a result of the waiver, the transaction is no longer ... offer on January 24, 2014 following the currently scheduled expiration time, ...
(Date:1/15/2014)... , January 15, 2014 BreedIT ... the exclusive worldwide distributor of highly sophisticated agro-breeding solutions ... January 7, 2014, the Company,s board of directors appointed ... as its new member of the board. ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... NATICK, Mass., Feb. 7, 2012 Boston Scientific Corporation (NYSE: ... Leerink Swann 2012 Global Healthcare Conference on February 15 in ... Mahoney, President, and Jeff Capello, Executive Vice President and Chief ... session regarding the Company beginning at approximately 11:00 a.m. ET. ...
... Feb. 7, 2012  Cardica, Inc. (Nasdaq: CRDC ) today ... and other conditions, shares of its common stock in an underwritten ... when the offering may be completed, or as to the size ... is acting as sole book-running manager for the offering. ...
Cached Medicine Technology:Boston Scientific to Participate in Leerink Swann 2012 Global Healthcare Conference 2Cardica Announces Proposed Public Offering of Common Stock 2
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit ... issues, published a comprehensive review today examining the current ... virus. The review calls for improved global surveillance strategies ... the recent outbreak of Ebola in West Africa that ... countries of Guinea and Liberia. According to the ...
(Date:4/17/2014)... team led by Cesar A. Arias, M.D., Ph.D., at ... (UTHealth) has identified a new superbug that caused a ... in the April 17 issue of The New ... is part of a class of highly-resistant bacteria known ... is a major cause of hospital and community-associated infections. ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... Radioimmunotherapy is a technique used in treating cancer , in ... are injected into patients.// These antibodies target and destroy ... particles . The main advatage of this treatment is ... ,A study in mice showed that this approach could be ...
... some of the reasons why hundreds of people// in ... to orthopaedic experts here. ,"Indian orthopaedics is ... complicated surgeries being performed here daily," said Surya Bhan, ... Institute of Medical Sciences (AIIMS) here. ,Bhan ...
... of deaths due to alcoholism has raised twofold in the ... that the number of deaths due to alcohol was 4,144 ... by last year. ,According to the experts, the lower ... alcohol consumption. Premature deaths are mainly caused by binge drinking ...
... been shown to prevent 70 per cent of cervical ... according to reports from Labor today. ,The government's ... Australian manufacturer CSL to make the vaccine Gardasil freely ... ,Gardasil, the vaccine designed in Australia halts the ...
... cells trial will be conducted within weeks on 100 patients ... yesterday.// ,This ?1.2 million trial of stem cells ... marrow will be backed by ?500,000 from philanthropists and aims ... of prompt action to cut deaths and suffering. ...
... such as ranitidine (Zantac) and cimetidine (Tagamet)and proton pump ... to increase the risk of cancer of the esophagus or ... H2 blockers and proton pump inhibitors do not increase the ... probably due to other related factors. 'There have been concerns ...
Cached Medicine News:Health News:A New Option For AIDS Treatment - Radioimmunotherapy 2Health News:Mismanagement of fractures a major concern, say experts 2Health News:Deaths due to heavy drinking has doubled in 15 years 2Health News:Heart Attack Damage Repaired with Stem cells 2Health News:Long-time Gastric Acid Suppression Does Not Increase The Risk Of Cancer 2
... Compensating for movement is ... in wheelchairs. Thats why ... exclusive technology to do ... with state-of-the-art technology, these ...
... wheelchair scale accommodates standard to extra-wide wheelchairs ... devices. The low-profile, heavy-duty, anodized aluminum weighing ... 1/2" high providing easy access for large ... stainless steel digital readout. The 6772 has ...
This high-capacity stand-on scale provides extra sensitivity and support to patients who are unsteady on their feet. Advanced technology compensates for patient movement....
... 100 provides a new screening, diagnostic, treatment ... medical management of sleep-related breathing disorders. The ... unmet need for an ambulatory, reliable, patient ... to the great number of OSA sufferers, ...
Medicine Products: